Table 1.
Primer | Nucleotide sequence | Orientation | GenBank reference |
---|---|---|---|
SJS 009 | 5′-TGAAGAAGTGGATACAGAAGG-3′ | Forward | (1807–1827 PT cDNA) |
SJS 010 | 5′-CTGGTTACAAGCCTGATGAAG-3′ | Forward | (1632–1653 PT cDNA) |
SJS 013 | 5′-GGTACGAGCGAAACATTGAAAAGATAT-3′ | Forward | (1278–1305 PT cDNA) |
SJS 014 | 5′-GGGCGAAAAACCGTCTATCAGGG-3′ | Reverse | (1727–1750 pCI-Neo) |
SJS 015 | 5′-CCATTATAAGCTGCGCGCGACAAGTTAACAAC-3′ | Forward | (1271–1300 pCI-Neo) |
SJS 016 | 5′-GTTGTTAACTTGTCGCGCGCAGCTTATAATGG-3′ | Reverse | (1271–1300 pCI-Neo) |
SJS 017 | 5′-ATAACATGCGGCCGCTTCCTGAGCCCAGAGAGCT-GCCCATGAATAGCACTGGGAGCATTGAGGCTCGCTG-AGAGTCACTTTTATTG-3′ | Reverse | (26764–26844 PT genomic) |
SJS 018 | 5′-ATAACATGCGGCCGCTTCCTGAGCCCAGAGAGC-TGCCCATGAATAGCACTGGGAGCATTGAGGCTTG-CTGAGAGTCACTTTTATTG-3′ | Reverse | (26764–26844 PT genomic) |
SJS 025 | 5′-GCAGCATCGAGGCACTAAAACTATGG-3′ | Forward | (1897–1922 PT cDNA) |
SJS 026 | 5′-AGTGCCTCGATGCTGCTTCTTTCACGG-3′ | Reverse | (1886–1902 PT cDNA) |
SJS 056 | 5′-TTTATAGCGGCCGCTGCTGAGAGTCACT-3′ | Reverse | (1934–1947 PT cDNA) |
SJS 069 | 5′-CGGATGGAAGCCGGTCTTGT-3′ | Forward | (2901–2920 pCI-Neo) |
SJS 089 | 5′-ATAAGAATGCGGCCGCAAGTAAAACCTCTACAAATG-3′ | Forward | (1364–1382 pCI-Neo) |
SJS 090 | 5′-GTCGGGGCTGGCTTAAC-3′ | Reverse | (3434–3450 pCI-Neo) |
SJS 125 | 5′-GCGATAGAAGGCGATGCGCT-3′ | Reverse | (3217–3236 pCI-Neo) |
Nest 13 FNest | 5′-TGCCTGTGAAGGTGACAGTG-3′ | Forward | (1667–1686 PT cDNA) |
Nest 13F.1 | 5′-ACCCTTTGTCATGAAGAGCC-3′ | Forward | (1690–1710 PT cDNA) |
The name, nucleotide sequence, orientation and GenBank nucleotide reference are provided. The mutations within the sequence are underlined and the restriction enzyme sites are italicized. Prothrombin cDNA (accession no. V00595), prothrombin genomic sequence (accession no. M17262) and pCI-Neo vector (Promega).